Clinical trials: Contrast-induced Nephropathy
Acute Kidney Failure
The Acetylcysteine for Contrast-Induced Nephropathy Trial
The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures that use contrast.
- Trial name
- ACT (NCT00736866)
- Testing
- Acetylcysteine
- Where
- Brazil
- Volunteers
- 2,300 people
- Sponsor
- Hospital do Coracao
Contrast Induced Nephropathy
Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN
Radio Contrast Induced Nephropathy (RCIN) remains a well recognized complication in patients undergoing diagnostic or interventional procedures requiring radiographic contrast agents.
- Trial name
- NCT00513825
- Testing
- Sodium Bicarbonate
- Where
- Iran
- Volunteers
- 72 people
- Sponsor
- Tehran University of Medical Sciences
Chronic Kidney Disease stage3, Contrast-induced Nephropathy
Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary intervention.
- Trial name
- NCT05264584
- Testing
- Isotonic saline, N-acetyl cysteine, Febuxostat 80 MG
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Acute Kidney Injury, Renal Insufficiency
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Kidney Diseases
- Trial name
- NORDICA (NCT02263820)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Sapere Bio
Acute Kidney Injury, Renal Insufficiency, Chronic
Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
This study evaluates the safety of iodinated contrast medium administered to liver transplant candidates with decreased renal function undergoing coronary CT angiography.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation
- Trial name
- NCT03806725
- Testing
- Intravenous administration of iodinated contrast medium for coronary CT angiography
- Where
- United States
- Sponsor
- Stanford University
Kidney Failure
Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization
The purpose of this study is to determine if patients should stop taking their angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) around the time of their angiogram in order to prevent contrast…
- Trial name
- NCT00317252
- Testing
- Hold ACEI or ARB
- Where
- Canada
- Volunteers
- 220 people
- Sponsor
- Hamilton Health Sciences Corporation
Renal Insufficiency, Acute Kidney Injury
Time to Excretion of Contrast, a Maastricht Prospective Observational Study
Risk of contrast-induced kidney injury is expected to be strongly correlated with exposure time. Studies on the excretion of iodinated contrast material are few and have mostly been carried out in patients with normal renal…
- Conditions
- Renal Insufficiency, Acute Kidney Injury, Contrast-induced Nephropathy
- Trial name
- TEMPOS (NCT04603261)
- Testing
- Contrast concentration in urine
- Where
- Netherlands
- Sponsor
- Maastricht University Medical Center
Kidney Diseases, Contrast Media Reaction
A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia
The study is analysis of the incidence of contrast-induced nephropathy (CIN) in patients with previously normal renal function undergoing angiography and comparison between the three different treatment protocols on renal…
- Trial name
- NCT02761577
- Testing
- Sodium bicarbonate, N-acetylcysteine
- Volunteers
- 90 people
- Sponsor
- Clinical Hospital Centre Zagreb
Renal Artery Stenosis
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.
- Trial name
- NCT00209391
- Testing
- Gadodiamide Injection
- Where
- Germany
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
Acute Kidney Injury, Contrast-induced Nephropathy
Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
Intravenous iodinated contrast media is commonly used to enhance diagnostic yield of computer tomography (CT) scans in clinical medicine.
- Trial name
- NCT04606056
- Where
- Singapore
- Volunteers
- 5,000 people
- Sponsor
- Changi General Hospital
Contrast Induced Nephropathy
Statins for Prevention of Contrast Induced Nephropathy
In this randomized study the investigators wish to explore the role of pre-procedural statin therapy for the prevention of contrast induced nephropathy in patients with moderate-to-severe renal dysfunction, submitted to elective…
- Trial name
- NCT00770796
- Testing
- Atorvastatin
- Volunteers
- 304 people
- Sponsor
- Ospedale Misericordia e Dolce
Coronary Artery Disease, Coronary Artery Angiography
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
In a double-blinded randomized clinical trial, all patients undergoing coronary artery catheterization who will met our criteria, will be enrolled into three groups to receive either, vitamin e, n-acetylcysteine, or placebo.
- Conditions
- Coronary Artery Disease, Coronary Artery Angiography, Coronary Catheterization, Contrast-induced Nephropathy
- Trial name
- NCT03755700
- Testing
- Vitamin E, N-acetyl cysteine, Normal Saline Flush, 0.9% Injectable Solution
- Where
- Iran
- Volunteers
- 1,000 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Aortic Aneurysm, Contrast Induced Nephropathy
Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
The purpose of the study is to determine if the dose of contrast (Omnipaque) administered for Computed Tomography Arteriograms (CTA) can be reduced without degradation of image quality.
- Conditions
- Aortic Aneurysm, Contrast Induced Nephropathy, Aortic and Arterial Anomalies
- Trial name
- NCT02669784
- Testing
- Low Dose Contrast (Omnipaque) 40mL, Low Dose Contrast (Omnipaque) 50 mL
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Milton S. Hershey Medical Center
Contrast-induced Nephropathy, Coronary Angiography
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
This study is designed to compare the bioavailability of the test Product(CE-Iohexol Injection) and the reference product Iohexol Injection (Omnipaque™) following intravenous injection in normal healthy volunteers.
- Trial name
- NCT03869983
- Testing
- Omnipaque™ (iohexol) Injection, CE-Iohexol
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CyDex Pharmaceuticals, Inc.
Contrast-induced Nephropathy, Acute Kidney Injury
Proenkephalin for Prediction of Contrast-Associated Kidney Events
Currently, contrast-induced kidney injury cannot be diagnosed on the day of cardiac catheterization. Recently, proenkephalin (penKid) was introduced as a new glomerular filtration marker.
- Conditions
- Contrast-induced Nephropathy, Acute Kidney Injury, Coronary Artery Disease
- Trial name
- PANCAKE (NCT03989505)
- Testing
- blood-draw for biomarker analyses
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- Dr. med. Mahir Karakas
Contrast Induced Nephropathy
Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention
To investigate the predictive value of the contrast media volume to creatinine clearance (V/CrCl) ratio for the risk of contrast-induced nephropathy (CIN) (i.e., within 48-72 h) and to determine a relatively safe V/CrCl cut-off…
- Trial name
- CONVIN (NCT01399203)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Guangdong Provincial People's Hospital
Chronic Renal Disease
Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with chronic kidney disease…
- Trial name
- NEIHR (NCT01402219)
- Testing
- Iopamidol injection 76%, iodixanol
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Guangdong Provincial People's Hospital
Contrast-induced Nephropathy
Predictive Value of CHA2DS2-VASC Score and Contrast Volume to Creatinine Clearance Ratio in Relation to Mehran Score for Contrast-Induced Nephropathy In ST- Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention
all patient presented with ST elevated myocardial infarction and underwent PPCI will be calculated with CHA2DS2-VASC score and contrast volume / creatinine clearance as apredictive value for Contrast induced nephropathy and the…
- Trial name
- NCT03266458
- Testing
- Primary percutaneous coronary intervention
- Where
- Egypt
- Volunteers
- 210 people
- Sponsor
- Assiut University
Radiographic Contrast Agent Nephropathy
Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System
The investigators hypothesize that a Clinical Decision Support System (CDSS) designed with "Patient-Specific" reminders yields superior performance than that with "Non-patient-specific" reminders in preventing contrast-induced…
- Trial name
- NCT01778140
- Testing
- Patient-specific computerized reminder, Non-patient-specific computerized reminder
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Contrast Induced Nephropathy
REduction of rIsk for Contrast Induced Nephropathy
The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous coronary intervention (PCI).
- Trial name
- REICIN-RESCIND (NCT01402232)
- Where
- 12 sites in China
- Volunteers
- 5,000 people
- Sponsor
- Guangdong Provincial People's Hospital